Same Trial, Different Endpoints: FDA Guided Idhifa To Full Approval By Recasting Clinical Analyses

US FDA conducted extensive re-analyses of Celgene's AML therapy Idhifa, resulting in full approval based on complete remission findings instead of the accelerated approval based on overall response rate sought by the NDA.